Drug intelligence / Profile preview

OTR-005

Development stage: Preclinical
Lead developer: OTR Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

OTR-005 is an oral small molecule therapeutic candidate currently in the discovery or preclinical stage of development by OTR Therapeutics. It is being investigated for applications in immunology and inflammation. While OTR Therapeutics is widely recognized for its ReGeneraTing Agent (RGTA) platform—which utilizes heparan sulfate mimetics to stabilize the extracellular matrix and promote tissue repair—OTR-005 represents a distinct small molecule program within the company's pipeline. As of 2024, the specific molecular target and precise mechanism of action for OTR-005 remain undisclosed by the developer.

Beyond the preview

Go deeper on OTR-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OTR-005.

Explore the full profile